



Press release from Emotra AB (publ)  
Göteborg, March 20, 2014

## Co-operation agreement with psychiatric clinic in Tübingen

**Emotra has signed a co-operation agreement with a psychiatric clinic at the university hospital in Tübingen in Germany. This is the second German clinic, and the 17<sup>th</sup> altogether, to sign an agreement to participate in Emotra's clinical multi-centre study for the purpose of evaluating the use of EDOR to assess potential suicide risks.**

So far, 17 clinics have signed co-operation agreements with Emotra. The Company aimed to involve 15 clinics in the clinical trials of Emotra's testing method, EDOR, and we have now decided to close the process of accepting new clinics in a few days. However, as interest in participating has proved greater than anticipated, we are open to include a small number of clinics this autumn.

The trials are planned to take place during the coming two years. We are presently discussing and negotiating with other clinics, and may very well add one or two clinics to our trials. Emotra's product has now received CE marking. We will be holding a first training/kick-off meeting as soon as we can gather most of the participating clinics. The individual clinics will then start testing patients as soon as their respective ethical committees have given the green light.

Emotra has entered a dynamic phase with an increasing number of clinical partners. In this phase, the Company is being run with a skeleton crew and as cost-effectively as possible in order not to jeopardise its long-term financial health. Once Emotra's method has received sufficiently strong scientific backing from the clinics evaluating EDOR, we will initiate a launch of the method in Europe.

**For further information, please contact:**

*Claes Holmberg, CEO*

*Telephone: +46 708 25 45 47*

*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

*Lars-Håkan Thorell, Head of Research*

*Telephone: +46 733 95 31 20*

*E-mail: [lars@emotra.se](mailto:lars@emotra.se)*

---

*Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*